Knight Therapeutics Stock Net Income
| GUD Stock | CAD 5.92 0.01 0.17% |
As of the 4th of February, Knight Therapeutics secures the Downside Deviation of 1.07, risk adjusted performance of 0.0277, and Mean Deviation of 0.8173. Knight Therapeutics technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices.
Knight Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.3628 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 3.9 M | 3.7 M | |
| Net Income Applicable To Common Shares | 5 M | 5.2 M | |
| Net Income Per Share | 0.05 | 0.05 | |
| Net Income Per E B T | 1.90 | 2.00 |
Knight | Net Income |
Evaluating Knight Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Knight Therapeutics's fundamental strength.
Latest Knight Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Knight Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Knight Therapeutics financial statement analysis. It represents the amount of money remaining after all of Knight Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Knight Therapeutics' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Knight Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 4.33 M | 10 Years Trend |
|
Net Income |
| Timeline |
Knight Net Income Regression Statistics
| Arithmetic Mean | 44,147,295 | |
| Geometric Mean | 26,794,904 | |
| Coefficient Of Variation | 128.07 | |
| Mean Deviation | 48,065,633 | |
| Median | 18,560,000 | |
| Standard Deviation | 56,540,001 | |
| Sample Variance | 3196.8T | |
| Range | 155.8M | |
| R-Value | (0.86) | |
| Mean Square Error | 888.3T | |
| R-Squared | 0.74 | |
| Slope | (9,628,426) | |
| Total Sum of Squares | 51148.3T |
Knight Net Income History
Knight Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Knight Therapeutics is extremely important. It helps to project a fair market value of Knight Stock properly, considering its historical fundamentals such as Net Income. Since Knight Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Knight Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Knight Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Knight Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Knight Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Knight Therapeutics.
| 11/06/2025 |
| 02/04/2026 |
If you would invest 0.00 in Knight Therapeutics on November 6, 2025 and sell it all today you would earn a total of 0.00 from holding Knight Therapeutics or generate 0.0% return on investment in Knight Therapeutics over 90 days. Knight Therapeutics is related to or competes with Cipher Pharmaceuticals, Vitalhub Corp, Aurora Cannabis, Canopy Growth, Kneat, TerrAscend Corp, and OrganiGram Holdings. Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally More
Knight Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Knight Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Knight Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.07 | |||
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 6.25 | |||
| Value At Risk | (1.47) | |||
| Potential Upside | 1.9 |
Knight Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Knight Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Knight Therapeutics' standard deviation. In reality, there are many statistical measures that can use Knight Therapeutics historical prices to predict the future Knight Therapeutics' volatility.| Risk Adjusted Performance | 0.0277 | |||
| Jensen Alpha | 0.0118 | |||
| Total Risk Alpha | (0.04) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0759 |
Knight Therapeutics February 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0277 | |||
| Market Risk Adjusted Performance | 0.0859 | |||
| Mean Deviation | 0.8173 | |||
| Semi Deviation | 0.9368 | |||
| Downside Deviation | 1.07 | |||
| Coefficient Of Variation | 3025.89 | |||
| Standard Deviation | 1.13 | |||
| Variance | 1.27 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | 0.0118 | |||
| Total Risk Alpha | (0.04) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0759 | |||
| Maximum Drawdown | 6.25 | |||
| Value At Risk | (1.47) | |||
| Potential Upside | 1.9 | |||
| Downside Variance | 1.14 | |||
| Semi Variance | 0.8777 | |||
| Expected Short fall | (0.97) | |||
| Skewness | 0.7077 | |||
| Kurtosis | 1.74 |
Knight Therapeutics Backtested Returns
Knight Therapeutics has Sharpe Ratio of -0.0341, which conveys that the firm had a -0.0341 % return per unit of risk over the last 3 months. Knight Therapeutics exposes twenty-nine different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Knight Therapeutics' Mean Deviation of 0.8173, downside deviation of 1.07, and Risk Adjusted Performance of 0.0277 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 0.36, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Knight Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Knight Therapeutics is expected to be smaller as well. At this point, Knight Therapeutics has a negative expected return of -0.0356%. Please make sure to verify Knight Therapeutics' standard deviation, value at risk, kurtosis, as well as the relationship between the sortino ratio and semi variance , to decide if Knight Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.49 |
Average predictability
Knight Therapeutics has average predictability. Overlapping area represents the amount of predictability between Knight Therapeutics time series from 6th of November 2025 to 21st of December 2025 and 21st of December 2025 to 4th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Knight Therapeutics price movement. The serial correlation of 0.49 indicates that about 49.0% of current Knight Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.49 | |
| Spearman Rank Test | 0.09 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Knight Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Knight Therapeutics reported net income of 4.33 M. This is 98.73% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net income for all Canada stocks is 99.24% higher than that of the company.
Knight Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Knight Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Knight Therapeutics could also be used in its relative valuation, which is a method of valuing Knight Therapeutics by comparing valuation metrics of similar companies.Knight Therapeutics is currently under evaluation in net income category among its peers.
Knight Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Knight Therapeutics from analyzing Knight Therapeutics' financial statements. These drivers represent accounts that assess Knight Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Knight Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 659.7M | 595.1M | 557.7M | 539.6M | 620.5M | 905.9M | |
| Enterprise Value | 614.7M | 601.2M | 568.1M | 508.9M | 458.0M | 504.9M |
Knight Fundamentals
| Return On Equity | -0.0045 | ||||
| Return On Asset | -0.0072 | ||||
| Profit Margin | (0.01) % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 563.98 M | ||||
| Shares Outstanding | 99.29 M | ||||
| Shares Owned By Insiders | 45.77 % | ||||
| Shares Owned By Institutions | 15.88 % | ||||
| Number Of Shares Shorted | 2.28 M | ||||
| Price To Earning | 133.90 X | ||||
| Price To Book | 0.75 X | ||||
| Price To Sales | 1.42 X | ||||
| Revenue | 371.3 M | ||||
| Gross Profit | 175.86 M | ||||
| EBITDA | 64.38 M | ||||
| Net Income | 4.33 M | ||||
| Cash And Equivalents | 5.11 M | ||||
| Cash Per Share | 4.10 X | ||||
| Total Debt | 49.46 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 2.31 X | ||||
| Book Value Per Share | 7.69 X | ||||
| Cash Flow From Operations | 36.28 M | ||||
| Short Ratio | 37.90 X | ||||
| Earnings Per Share | (0.04) X | ||||
| Price To Earnings To Growth | 2,857 X | ||||
| Target Price | 7.93 | ||||
| Number Of Employees | 745 | ||||
| Beta | 0.13 | ||||
| Market Capitalization | 588.95 M | ||||
| Total Asset | 963.8 M | ||||
| Retained Earnings | 154.79 M | ||||
| Working Capital | 251.09 M | ||||
| Current Asset | 499.48 M | ||||
| Current Liabilities | 6.74 M | ||||
| Net Asset | 963.8 M |
About Knight Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Knight Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Knight Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Knight Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in Knight Stock
Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.